Abstract
Background: Men who have sex with men (MSM) with acute human immunodeficiency virus (HIV) infection (AHI) are a key source of new infections. To curb transmission, we implemented a strategy for rapid AHI diagnosis and immediate initiation of combination antiretroviral therapy (cART) in Amsterdam MSM. We assessed its effectiveness in diagnosing AHI and decreasing the time to viral suppression. Methods: We included 63 278 HIV testing visits in 2008-2017, during which 1013 MSM were diagnosed. Standard of care (SOC) included HIV diagnosis confirmation in < 1 week and cART initiation in < 1 month. The AHI strategy comprised same-visit diagnosis confirmation and immediate cART. Time from diagnosis to viral suppression was assessed for 3 cART initiation periods: (1) 2008-2011: cART initiation if CD4 < 500 cells/μL (SOC); (2) January 2012-July 2015: cART initiation if CD4 < 500 cells/μL, or if AHI or early HIV infection (SOC); and (3a) August 2015-June 2017: universal cART initiation (SOC) or (3b) August 2015-June 2017 (the AHI strategy). Results: Before implementation of the AHI strategy, the proportion of AHI among HIV diagnoses was 0.6% (5/876); after implementation this was 11.0% (15/137). Median time (in days) to viral suppression during periods 1, 2, 3a, and 3b was 584 (interquartile range [IQR], 267-1065), 230 (IQR, 132-480), 95 (IQR, 63-136), and 55 (IQR, 31-72), respectively (P <. 001). Conclusions: Implementing the AHI strategy was successful in diagnosing AHI and significantly decreasing the time between HIV diagnosis and viral suppression.
Original language | English |
---|---|
Pages (from-to) | 1952-1960 |
Number of pages | 9 |
Journal | Clinical Infectious Diseases |
Volume | 72 |
Issue number | 11 |
DOIs | |
Publication status | Published - 1 Jun 2021 |
Bibliographical note
Funding Information:The HIV Transmission Elimination Amsterdam (H-TEAM) Initiative is supported by Aids Fonds (grant number 2013169); the AmsterdamDiner Foundation, Bristol-Myers Squibb International Corporation (study number AI424-541); Gilead Sciences Europe Ltd (grant number PA-HIV-PREP-16-0024); Gilead Sciences (protocol numbers CONL- 276-4222 and CO-US-276-1712); Janssen Pharmaceuticals (reference number PHNL/JAN/0714/0005b/1912fde); the M.A.C. AIDS Fund, ViiV Healthcare (PO numbers 3000268822 and 3000747780); and ZonMw (grant number 522002003). The ATHENA cohort is managed by Stichting HIV Monitoring and is supported by a grant from the Dutch Ministry of Health, Welfare and Sport through the Centre for Infectious Disease Control of the National Institute for Public Health and the Environment.
Publisher Copyright:
© 2020 The Author(s). Published by Oxford University Press for the Infectious Diseases Society of America.